Insider Buying: Sanofi Acquires 168,511 Shares of Regeneron Pharmaceuticals Stock (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) major shareholder Sanofi purchased 168,511 shares of the company’s stock on the open market in a transaction dated Friday, February 7th. The shares were purchased at an average cost of $286.78 per share, for a total transaction of $48,325,584.58. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.40% on Monday, hitting $304.00. The stock had a trading volume of 1,487,774 shares. Regeneron Pharmaceuticals has a 52-week low of $154.16 and a 52-week high of $319.83. The stock’s 50-day moving average is $282.5 and its 200-day moving average is $279.8. The company has a market cap of $29.860 billion and a price-to-earnings ratio of 42.68.
REGN has been the subject of a number of recent research reports. Analysts at TheStreet reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Monday, February 3rd. Finally, analysts at BMO Capital Markets downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, January 15th. They now have a $331.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $305.66.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.